![]() Music |
![]() Video |
![]() Movies |
![]() Chart |
![]() Show |
![]() |
Obinutuzumab Extends Remission Time in Rituximab-Refractory iNHL (American Society of Hematology) View |
![]() |
Obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma (ecancer) View |
![]() |
Obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma (ecancer) View |
![]() |
Obinutuzumab extends PFS for follicular lymphoma in GALLIUM trial (ecancer) View |
![]() |
obinutuzumab plus bendamustine in rituximab-refractory indolent non-Hodgkin lymphoma (Oncoletter) View |
![]() |
Obinutuzumab bests rituximab for PFS in follicular lymphoma (MDedge: news and insights for busy physicians) View |
![]() |
Debate: Is obinutuzumab superior to rituximab in lymphoma - Yes (HMP Education) View |
![]() |
Treating CLL with obiutuzumab (ecancer) View |
![]() |
Obinutuzumab/chlorambucil gives OS benefit over rituximab in frontline CLL (VJHemOnc – Video Journal of Hematology \u0026 HemOnc) View |
![]() |
CD20-Targeted Antibodies With Novel Agents for CLL (OncLive) View |